590 related articles for article (PubMed ID: 23147106)
1. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia.
Suzuki Y; Kawasaki K; Sato Y; Tokimatsu I; Itoh H; Hiramatsu K; Takeyama M; Kadota J
Chemotherapy; 2012; 58(4):308-12. PubMed ID: 23147106
[TBL] [Abstract][Full Text] [Related]
2. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Ghosh N; Chavada R; Maley M; van Hal SJ
Clin Microbiol Infect; 2014 Dec; 20(12):O1098-105. PubMed ID: 24890030
[TBL] [Abstract][Full Text] [Related]
3. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
[TBL] [Abstract][Full Text] [Related]
4. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
Kullar R; Davis SL; Levine DP; Rybak MJ
Clin Infect Dis; 2011 Apr; 52(8):975-81. PubMed ID: 21460309
[TBL] [Abstract][Full Text] [Related]
5. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
Frymoyer A; Guglielmo BJ; Hersh AL
Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
[TBL] [Abstract][Full Text] [Related]
6. [Persistent bacteremia due to methicillin-resistant Staphylococcus aureus. A result of inadequate treatment].
Parra-Ruiz J; Tomas-Jiménez C; Muñoz-Medina L; Hernández-Quero J
Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):372-3. PubMed ID: 19339080
[No Abstract] [Full Text] [Related]
7. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
Clemens EC; Chan JD; Lynch JB; Dellit TH
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):408-14. PubMed ID: 21924852
[TBL] [Abstract][Full Text] [Related]
8. Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?
Hale CM; Seabury RW; Steele JM; Darko W; Miller CD
J Pharm Pract; 2017 Jun; 30(3):329-335. PubMed ID: 27074786
[TBL] [Abstract][Full Text] [Related]
9. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin AUC24 /MIC Ratio in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia.
Ji M; Kim HK; Kim SK; Lee W; Sung H; Chun S; Kim MN; Min WK
J Clin Lab Anal; 2016 Sep; 30(5):485-9. PubMed ID: 26499918
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
Lepe JA; Gil-Navarro MV; Santos-Rubio MD; Bautista J; Aznar J
Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
[TBL] [Abstract][Full Text] [Related]
13. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia.
Harigaya Y; Bulitta JB; Forrest A; Sakoulas G; Lesse AJ; Mylotte JM; Tsuji BT
Antimicrob Agents Chemother; 2009 Sep; 53(9):3894-901. PubMed ID: 19596879
[TBL] [Abstract][Full Text] [Related]
15. Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients.
Chung J; Oh JM; Cho EM; Jang HJ; Hong SB; Lim CM; Koh YS
Anaesth Intensive Care; 2011 Nov; 39(6):1030-7. PubMed ID: 22165354
[TBL] [Abstract][Full Text] [Related]
16. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.
Ploessl C; White C; Manasco K
Pediatr Infect Dis J; 2015 Oct; 34(10):e244-7. PubMed ID: 26121203
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
18. Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia.
Neuner EA; Casabar E; Reichley R; McKinnon PS
Diagn Microbiol Infect Dis; 2010 Jul; 67(3):228-33. PubMed ID: 20542203
[TBL] [Abstract][Full Text] [Related]
19. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Poon H; Chang MH; Fung HB
Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
[TBL] [Abstract][Full Text] [Related]
20. Establishment of an AUC
Chavada R; Ghosh N; Sandaradura I; Maley M; Van Hal SJ
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]